| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 26 Jul 2025 | 26 Jul 2025 |
| 1. Appointment of Mr. Vinod Kumar Sharma as Additional, non executive Independent director of the company 2. Resignation of Mr. Kiran Kumar Verma as Independent director of the company 3. Reconstitution of Audit Committee and Nomination & Remuneration Committee | ||
| Board Meeting | 19 May 2025 | 6 May 2025 |
| Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve the Standalone & Consolidated Audited Financial Results for the 4th Quarter and Financial Year Ended on 31st March 2025. AUDITED FINANCIAL RESULTS FOR YEAR ENDED 31ST MARCH 2025 (As per BSE Announcement Dated on 19/05/2025) | ||
| Board Meeting | 31 Jan 2025 | 20 Jan 2025 |
| Quarterly Results Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine months ended December 31, 2024 along with Limited Review Report (As Per BSE Announcement dated on 20.01.2025) Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 (Listing Regulations), this is to inform your that Board of Directors in its meeting held today i.e., January 31, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024 (As per BSE Announcement Dated on 31/01/2025) | ||
| Board Meeting | 30 Oct 2024 | 22 Oct 2024 |
| Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year e UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED 30-09-2024 (As Per BSE Announcement dated on 30.10.2024) | ||
| Board Meeting | 10 Aug 2024 | 2 Aug 2024 |
| Kwality Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June 2024. We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended as on 30.06.2024 along with the Auditors limited review reports thereon. (As Per BSE Announcement Dated on: 10/08/2024) Revised Results for Q. E. 30-06-2024 are attached herewith after correction of minor typographical error. This will have no effect on the figures of financial results of the company declared for q.e. 30-06-2024. (As Per Bse Announcement Dated on 12.08.2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.